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Dendritic cellsencephalopathy (PML) is a demyelinating disease of the brain caused by JC virus
(JCV) for which there is no cure. PML patients who have JCV-speciﬁc CD8+ cytotoxic T lymphocytes (CTL)
in their blood have a better clinical outcome. We compared JCV-speciﬁc CTL responses in vitro elicited
either by JCV peptide-loaded dendritic cells (DC) or by direct peptide stimulation of lymphocytes from 20
HLA-A⁎0201+ healthy controls, HIV+ and PML patients. JCV peptide-loaded DC elicited a stronger CTL
expansion in 13/15 responders. DC can induce a potent JCV-speciﬁc CTL response in vitro, and may constitute
a promising approach for PML immunotherapy.
© 2008 Elsevier Inc. All rights reserved.Introduction
JC virus is the agent of progressive multifocal leukoencephalopathy
(PML) (Koralnik, 2006) which occurs in up to 5% of people with AIDS
(Antinori et al., 2003), as well as in patients with lymphoproliferative
disorders, organ transplant recipients and individuals treated with
natalizumab (Berger and Koralnik, 2005). After asymptomatic primary
infection, JCV remains quiescent in the kidney, and can be found in
urine of 30% of healthy and immunosuppressed individuals alike
(Koralnik et al., 1999) and in lymphoid organs (Monaco et al., 1998).
In immunocompromised individuals, JCVmay reactivate from sites
of latency and causes a lytic infection of oligodendrocytes leading to
multiple areas of demyelination in the central nervous system, and
ultimately death within a few months. There is no effective treatment
for this disease and those patients who survive are often left with
devastating neurological sequellae (De Luca et al., 1998).
Therefore, a therapeutic vaccine may contain JCV replication,
especially in the early stage of the disease, and may reduce the
morbidity and mortality in patients with PML.cal Center, E/CLS – 1005, 330
4527.
alnik).
l rights reserved.The antibody response to JCV is unable to prevent development of
PML or prevent disease progression (Weber et al., 1997). Conversely,
the cellular immune responsemediated by JCV-speciﬁc CD8+ cytotoxic
T-lymphocytes (CTL) plays a crucial role in the containment of PML
(Du Pasquier et al., 2003; Du Pasquier et al., 2004; Koralnik et al.,
2002). Hence, a treatment that improves the CTL response against JCV
may be of beneﬁt in patients with PML. Such therapies may consist of
adoptive transfer of T cells after ex vivo stimulation with JCV antigens
or dendritic cells (DC)-based immunotherapy (June, 2007; O'Neill and
Bhardwaj, 2005). DC are the professional antigen-presenting cells in
the body. A small number of DC and low level of antigens are able to
induce a potent CD8+ T-cell response in vitro and in vivo (Adams et al.,
2005). In addition, the safety of DC immunization has been established
in numerous clinical trials (Dhodapkar and Bhardwaj, 2000). Further-
more, promising trials of DC vaccination have already been reported in
patients with HIV infection (Lu et al., 2004).
The frequency of JCV-speciﬁc CTL in fresh blood is very low, and
their function cannot usually be measured ex vivo by conventional
assays without prior stimulation with JCV antigens (Lima et al., 2007).
In our quest for a treatment for PML, we ﬁrst developed a DC-based
stimulation of JCV-speciﬁc T cells. Then, to determine the respective
potential of autologous transfer of T cells and DC-based immunothe-
rapy for PML, we compared the CTL response elicited in vitro from
peripheral blood lymphocytes against JCV CTL epitopes by direct
174 A. Marzocchetti et al. / Virology 383 (2009) 173–177peptide stimulation, as performed in adoptive transfer of T cells, and
by JCV-peptide loaded mature monocyte-derived DC.
Results
Peripheral blood samples were obtained from 20 JCV seropositive
HLA-A⁎0201+ subjects, including 6 with PML (5 HIV+ and 1 HIV−) aged
40 to 69 years (47.8±12.1 years [mean±SD]), 4 HIV+ individuals aged
44 to 50 years (45.5±3 years) and 10 healthy controls (HC) aged 24 to
44 (34±8 years). HIV+/PML and HIV+ patients had a mean CD4+ T cell
count of 521/μL±289 and 496/μL±320 respectively, and a plasma HIV
RNA level of 1.25 log10 copies/ml±0.5 and 1.98 log10 copies/ml±1.9,
respectively. All HIV+ and HIV+/PML patients were on highly active
antiretroviral therapy (HAART). All but one PML patients were still
alive an average of 9.2 years (3.4 to 15.2 years) after disease onset.
JCV-speciﬁc CTL responses against VP1p36 and/or VP1p100 epitopes,
were detected in 14/20 study subjects, including 5/6 PML patients, 3/4
HIV+ individuals and 6/10 HC after direct peptide stimulation of
lymphocytes. These responses were enhanced using peptide-loaded
DC stimulation in 14/16 comparisons performed in these 14
individuals (Table 1). The average ampliﬁcation factor of JCV-speciﬁc
CD8+ T-cell response using peptide-loaded DC compared to peptide
stimulation alone was 6.8× for PML patients, 3.9× for HIV+ patients,
and 31.0× for HC. Furthermore, we measured a JCV epitope-speciﬁc
CTL response after DC stimulation in 1 HIV+ individual (#1, VP1p100)
and 2 HC (#3, VP1p100 and #9, VP1p36) who had no detectable CTL
after stimulation of lymphocytes with peptide alone. The median
percentage of JCV-speciﬁc CD8+ T cells in peptide alone and peptide-
loaded-DC stimulation of lymphocytes was 0.7% (0.1–40.1%) vs 7.3%
(0.2–48.8%) in the whole study population including both JCV VP1p36
and VP1p100 epitopes. There was a signiﬁcant increase in the JCV-
speciﬁc CTL response for both epitopes in peptide-loaded DC versusTable 1
Detection of JCV VP1p36- and JCV VP1p100-speciﬁc CD8+ T cells in lymphocyte cultures stimu
Subjects % JCV VP1p36-speciﬁc CD8+ T cells Ampliﬁcation fact
Peptide alone Peptide-loaded DC
PML patient #
1 0.1 0.4 4.0×
2 0.4 1.2 3.0×
3 –b ∅
4 1.0 24.5 24.5×
5 – – ∅
6 40.1 3.6 0.1×
HIV+ patient #
1 NA NA
2 NA NA
3 NA NA
4 NA NA
Healthy control #
1 0.7 48.8 69.7×
2 0.2 15.0 75.0×
3 0.8 22.1 27.6×
4 0.5 12.3 24.6×
5 – – ∅
6 – – ∅
7 – – ∅
8 – – ∅
9 – 2.6 –c
10 – – ∅
Notes. ∅, no ampliﬁcation.
The ampliﬁcation factor, deﬁned as the ratio between frequency of JCV speciﬁc CTL frequenc
75× in patients with detectable JCV response.
a NA, not available.
b –, undetectable.
c JCV VP1p36 and VP1p100-speciﬁc CD8+ T cells detectable after peptide-loaded DC stimulapeptide alone stimulation of lymphocytes in all 15 responders
(p=0.004, Wilcoxon matched-paired test).
In 1 PML patient and 4 HC, we did not observe any JCV-speciﬁc CTL
response using either method. Strong CTL responses to positive
control Flu matrix protein (MP) peptide were elicited using peptide-
loaded DC stimulation in all tested cases, while no responses were
elicited against negative control NY ESO cancer peptide, as expected
(data not shown). A representative example of CTL response elicited
by direct peptide or peptide-loaded DC stimulation of lymphocytes is
shown in Fig. 1.
Interestingly, among the PML group, we detected the strongest
JCV-speciﬁc CTL response using DC, in PML patient #4 diagnosed only
2 months before testing. In contrast, PML #5 who developed PML
15.2 years before testing had no detectable JCV-speciﬁc CTL response
with either peptide or peptide-loaded DC stimulation. Only two study
subjects, PML patient #6 and HC #7 had a stronger CTL response
against JCV epitopes using peptide alone compared to peptide-pulsed
DC stimulation. A representative example of the increase in the JCV
VP1p36 or JCV VP1p100-speciﬁc CTL response obtained using peptide-
loaded DC compared to peptide alone stimulation of lymphocytes is
shown in Fig. 2A, for one subject of each study group. To verify the
function of the tetramer-staining cells, a 51Cr release assay was
performed after both types of stimulation in a sample from HC#1
(Fig. 2B). Only the peptide-loaded DC stimulation was potent enough
to generate a sufﬁcient number of functionally active effector CD8+ T
cells that could be detected by the 51Cr assay. While peptide-speciﬁc
CTL are usually undetectable in fresh blood samples in most
individuals (Du Pasquier et al., 2003) our ﬁndings suggest that
stimulation of peripheral blood lymphocytes in vitro with peptide-
loaded autologous DC elicit inmost cases a stronger CTL response than
stimulation with peptide alone in individuals of the 3 study groups.
The lack of any detectable JCV CTL expansion in lymphocytes of 4 HClated with peptide-loaded autologous DC or peptide alone
or % JCV VP1p100-speciﬁc CD8+ T cells Ampliﬁcation factor
Peptide alone Peptide-loaded DC
NAa NA
2.2 16.5 7.5×
0.6 1.0 1.7×
NA NA
– – ∅
NA NA
– 0.2 c
0.4 3.2 8.0×
3.6 8.0 2.2×
4.2 7.3 1.7×
NA NA
4.9 7.4 1.5×
0.3 c
NA NA
NA NA
NA NA
8.6 6.6 0.7×
NA NA
2.6 47.1 18.1×
NA NA
y after stimulation with peptide-loaded DC versus peptide alone, and varies from 0.1 to
tion only.
Fig. 2. JCV peptide-speciﬁc CTL response are enhanced in subjects from 3 study groups
by stimulating peripheral blood lymphocytes with JCV peptide-loaded autologous DC
compared to peptide alone. (Panel A) Staining of peripheral blood lymphocytes from
PML #4, HIV #2, HC #1with tetrameric HLA-A⁎0201/JCV VP1p36 or VP1p100 complexes is
shown after in vitro stimulation with either the JCV VP1p36 or VP1p100 peptide alone or
with JCV VP1p36 or VP1p100-loaded autologous DC for 10 to 14 days. The percentage of
CD8α+ T cells that bind the tetramer (right upper quadrant of each panel) are indicated.
(Panel B) Stimulated lymphocytes from HC #1 were then assessed for the presence of
functionally active effectors cells in a 51Cr release assay. Lysis of JCV VP1p36-pulsed
autologous B lymphoblastoid cell line (B-LCL) could be detected only using lymphocytes
from HC# 1 stimulated with JCV VP1p36-loaded DC but not by those stimulated with
peptide alone. The percentage of speciﬁc lysis indicates the difference in speciﬁc 51Cr
release between target cells pulsed with JCV VP1p36 peptide and those pulsed with an
irrelevant control peptide18). Effector target (E:T) ratios are shown.
Fig. 1. Comparison of JCV VP1p36, JCV VP1p100, NY ESO 1 and Flu matrix protein-speciﬁc
CTL responses in PML patient #2 after stimulation of lymphocytes with peptide alone or
peptide-loaded autologous DC. Staining of peripheral blood lymphocytes from PML
patient #2 with tetrameric HLA-A⁎0201 JCV VP1p36, JCV VP1p100, NY ESO 1, and Flu
matrix protein complexes is shown after in vitro stimulation with either the peptide
alone orwith autologous peptide-loadedDC for 10 to 14 days. The percentage of CD8α+ T
cells that bind the tetramer (right upper quadrant of each panel) is indicated. An increase
in JCV epitope-speciﬁc CTL and Flu matrix protein positive control could be seen using
peptide-loaded DC compared to peptide stimulation alone, while no CTL response could
be elicited against negative control cancer epitope NY ESO 1 using either method.
175A. Marzocchetti et al. / Virology 383 (2009) 173–177and 1 PML patient could be explained by an immune response
directed toward other JCV epitopes or by a very low frequency of JCV
epitope-speciﬁc CTL response in fresh blood. Our results conﬁrm and
expand previous reports showing that phenotypic and functional
maturation of monocyte-derived DC from HIV-1 infected individuals
is similar to healthy volunteers (Hsieh et al., 2003).Discussion
Since there is no speciﬁc antiviral treatment against JCV,
enhancement of the cellular immune response against the virus
may represent an important therapeutic option for PML. Indeed, we
have demonstrated that an early detection of JCV-speciﬁc CTL has an
176 A. Marzocchetti et al. / Virology 383 (2009) 173–17787% predictive value for subsequent control of PML (Du Pasquier et al.,
2004). In addition, these cells have an effector memory phenotype
early after disease onset (Lima et al., 2007) and are present in the
cerebrospinal ﬂuid of PML survivors (Du Pasquier et al., 2005).
Furthermore, CD8+ T cells tend to aggregate around JCV infected glial
cells in PML lesions (Wuthrich et al., 2006). Our current results suggest
that it may be possible to signiﬁcantly expand the JCV-speciﬁc CTL
response in PML patients even during the early stage of the disease. In
turn, these CTL may penetrate into the brain where they may destroy
virus-infected glial cells and help contain PML. This is to our
knowledge the ﬁrst demonstration that JCV-speciﬁc CTL can be
elicited by DC stimulation of lymphocytes. This is remarkable since the
frequency of JCV-speciﬁc memory T cells is very low in the peripheral
blood, in some cases less than 1/100,000 PBMC (Du Pasquier et al.,
2003). Furthermore, these results also demonstrate that CTL speciﬁc
for a pathogen different than HIV can be elicited in immunosup-
pressed HIV-infected patients. It could be argued that those patients
who are able to mount a CTL response against JCV will not need an
additional immunotherapy for PML. However we have observed that
this response may not be constant and that relapses of PML do occur
(Du Pasquier et al., 2004). In addition, PML survivors are often left with
devastating neurological sequellae. Therefore, our goal would be to
administer the DC-based immunotherapy to PML patients soon after
diagnosis to prevent the occurrence of irreversible neurological
dysfunction. While the most dramatic effect of peptide-loaded DC
were observed in healthy controls, a new category of patients at risk
for PML include individuals with MS and Crohn's disease treated with
natalizumab (Berger and Koralnik, 2005). We have previously shown
that the baseline response to JCV in MS patients is at least as good as
healthy controls (Du Pasquier et al., 2006). Therefore, such patients
may also beneﬁt from DC-based immunotherapy.
Our study of in vitro expansion of JCV-speciﬁc CTL by peptide-
loaded autologous DC is novel and constitutes the proof of concept
necessary to bring DC-based immunotherapy for PML to the clinical
stage. The potential beneﬁts of such immunotherapy in patients with
PML are substantial since a persistent JCV-speciﬁc CTL response may
limit the extent of the neurological damage caused by JCV and
eventually improve their survival.
Materials and methods
JCV serology was determined by HIA or ELISA as previously
described (Miller et al., 1983; Viscidi et al., 2003).
For direct peptide stimulation, peripheral blood lymphocytes were
isolated by centrifugation on Ficoll-diatrizoate gradient and cultured
in RPMI-12% fetal calf serum with A⁎0201-restricted JCV VP1p36 (Du
Pasquier et al., 2003)and VP1p100 (Koralnik et al., 2002) or control
epitope peptides NY ESO 1 (Velazquez et al., 2007) and FluMP (58–66)
(Dhodapkar and Bhardwaj, 2000) at a concentration of 1 to 2.5 μg/ml,
and after 3 days, with 25 U of rhIL-2/ml.
For peptide-loaded DC stimulation, DC were derived from periph-
eral bloodmononuclear cells (PBMC) using two different methods. For
PML patients #2 to #5 and all HC, PBMC were plated and allowed to
adhere to plastic for 1–2 h at 37 °C in 5% pooled human serum (HPS).
For PMLpatient #1 and all HIV+ patientsmonocyteswere isolated from
PBMC using CD14 Human Microbeads (MACS, Milteny Biotech).
Plastic-adherent or CD14+ cells (monocyte-enriched fraction) were
cultured as previously described (O'Neill and Bhardwaj, 2005). On day
7, DC had a mature phenotype assessed based on three parameters:
1) Morphology: mature DC were loosely attached to the wells, veiled
and clustered.
2) Immunophenotyping: phenotypic analysis of immature and
mature DC was performed by ﬂow cytometry. Brieﬂy, DC were
considered mature when they were CD83+, CD80+, CD86+, MHC
class I+, MHC class II+, CCR7+.3) Mixed leukocyte reaction: in addition, the functionality of mature
DC was tested in each category of study subjects in a mixed
lymphocyte reaction (Waeckerle-Men et al., 2004).
Mature DC were incubated with 1 to 2.5 μg/ml of JCV or control
peptide for 2 to 4 h at 37 °C.
After washing, DC were resuspended in RPMI-5% HPS and mixed
with autologous non-adherent cells or CD14− fraction (T cells enriched
fraction) at a ratio 1:10 and supplemented with IL2 (50 U/ml) starting
at day 3. After 10–14 days in culture, lymphocytes stimulated by
peptide alone of peptide-loaded autologous DC were tested for the
presence of peptide-speciﬁc CTL by tetramer staining and 51Cr release
assay as previously described (Du Pasquier et al., 2004).
Statistical analysis
The Wilcoxon matched-paired test was employed to calculate the
difference between the median of JCV-speciﬁc CTL response for both
epitopes in peptide-loaded DC versus peptide alone stimulation of
lymphocytes in all 15 responders. This non-parametric test was used
since the data were sampled from a non-Gaussian distribution. The
test was two tailed and α of 0.05 was employed. Calculations were
performed with GraphPad prism 5.0 for PC (GraphPad Software, San
Diego, CA).
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